Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Pds Biotechnology Corp (PDSB)

Pds Biotechnology Corp (PDSB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 56,680
  • Shares Outstanding, K 45,710
  • Annual Sales, $ 0 K
  • Annual Income, $ -37,610 K
  • EBIT $ -35 M
  • EBITDA $ -34 M
  • 60-Month Beta 1.21
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.66

Options Overview Details

View History
  • Implied Volatility 376.42% ( +53.34%)
  • Historical Volatility 78.05%
  • IV Percentile 91%
  • IV Rank 47.11%
  • IV High 735.99% on 04/14/25
  • IV Low 56.17% on 08/23/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 6
  • Volume Avg (30-Day) 100
  • Put/Call OI Ratio 0.01
  • Today's Open Interest 7,319
  • Open Int (30-Day) 6,803

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/25
See More
  • Average Estimate -0.24
  • Number of Estimates 2
  • High Estimate -0.23
  • Low Estimate -0.25
  • Prior Year -0.23
  • Growth Rate Est. (year over year) -4.35%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.1800 +5.08%
on 07/02/25
1.8500 -32.97%
on 06/12/25
-0.5100 (-29.14%)
since 06/11/25
3-Month
1.0000 +24.00%
on 04/16/25
1.9150 -35.25%
on 06/11/25
+0.2100 (+20.39%)
since 04/11/25
52-Week
0.8500 +45.88%
on 04/07/25
4.4200 -71.95%
on 07/16/24
-2.6400 (-68.04%)
since 07/11/24

Most Recent Stories

More News
PDS Biotech Announces Colorectal Cancer Cohort of Phase 2 Clinical Trial with PDS01ADC Met Criteria for Expansion to Stage 2 Following Positive Stage 1 Results

PDSB : 1.2400 (-4.62%)
PDS Biotech to Host Key Opinion Leader Event to Discuss Versamune® HPV for the Treatment of HPV16+ HNSCC

PDSB : 1.2400 (-4.62%)
2 Biopharmaceutical Stocks Focused on Cancer That Wall Street Predicts Will More Than Double

Analysts are uber bullish on Actuate Therapeutics and PDS Biotechnology stocks for the next 12 months. Here’s why.

PDSB : 1.2400 (-4.62%)
ACTU : 6.14 (-0.65%)
BMY : 46.86 (-3.42%)
BNTX : 112.89 (-0.90%)
PDS Biotech Unveils Updated Positive Data From VERSATILE-002 Trial and Additional Trials Evaluating Versamune® HPV to Treat Head and Neck Cancers at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

PDSB : 1.2400 (-4.62%)
PDS Biotech Announces Positive Extended Follow-Up Data for VERSATILE-002 and Additional Trials Evaluating Versamune® HPV to be Presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

PDSB : 1.2400 (-4.62%)
PDS Biotech to Participate at the A.G.P. Virtual Annual Healthcare Company Showcase

PDSB : 1.2400 (-4.62%)
PDS Biotechnology: Q1 Earnings Snapshot

PDS Biotechnology: Q1 Earnings Snapshot

PDSB : 1.2400 (-4.62%)
PDS Biotech Reports First Quarter 2025 Financial Results and Provides Clinical Programs and Corporate Update

PDSB : 1.2400 (-4.62%)
PDS Biotechnology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

PDSB : 1.2400 (-4.62%)
PDS Biotech Announces Additional Details on Two Preclinical Universal Influenza Presentations at IMMUNOLOGY2025â„¢ Annual Meeting

PDSB : 1.2400 (-4.62%)

Business Summary

PDS Biotechnology Corp. is an immuno-oncology company. It is focused on developing a pipeline of clinical-stage immunotherapies to treat cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, cancer and other cancers. The company's products are based on the proprietary...

See More

Key Turning Points

3rd Resistance Point 1.3600
2nd Resistance Point 1.3300
1st Resistance Point 1.2850
Last Price 1.2400
1st Support Level 1.2100
2nd Support Level 1.1800
3rd Support Level 1.1350

See More

52-Week High 4.4200
Fibonacci 61.8% 3.0563
Fibonacci 50% 2.6350
Fibonacci 38.2% 2.2137
Last Price 1.2400
52-Week Low 0.8500

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar